Charles Schwab
FHTX icon

Charles Schwab’s Foghorn Therapeutics FHTX Stock Holding History

Charles Schwab’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$536K Buy
109,781
+6,256
+6% +$27.8K ﹤0.01% 3221
2026
Q1 		$495K Buy
103,525
+21,162
+26% +$116K ﹤0.01% 3107
2025
Q4 		$445K Sell
82,363
-15,821
-16% -$71.7K ﹤0.01% 3191
2025
Q3 		$480K Buy
98,184
+7
+0% +$37 ﹤0.01% 3188
2025
Q2 		$461K Buy
98,177
+22,682
+30% +$94.8K ﹤0.01% 3163
2025
Q1 		$276K Hold
75,495
– – ﹤0.01% 3223
2024
Q4 		$356K Hold
75,495
– – ﹤0.01% 3237
2024
Q3 		$703K Buy
75,495
+7,000
+10% +$50.7K ﹤0.01% 3034
2024
Q2 		$394K Buy
68,495
+13,053
+24% +$77.8K ﹤0.01% 3288
2024
Q1 		$372K Hold
55,442
– – ﹤0.01% 3128
2023
Q4 		$358K Hold
55,442
– – ﹤0.01% 3185
2023
Q3 		$277K Hold
55,442
– – ﹤0.01% 3231
2023
Q2 		$390K Buy
55,442
+513
+0.9% +$3.59K ﹤0.01% 3161
2023
Q1 		$341K Hold
54,929
– – ﹤0.01% 3058
2022
Q4 		$350K Buy
54,929
+1,826
+3% +$13.8K ﹤0.01% 3082
2022
Q3 		$456K Sell
53,103
-24
-0% -$309 ﹤0.01% 3029
2022
Q2 		$723K Buy
53,127
+1,257
+2% +$16.2K ﹤0.01% 2918
2022
Q1 		$790K Buy
51,870
+1,059
+2% +$14.5K ﹤0.01% 2946
2021
Q4 		$1.16M Buy
50,811
+853
+2% +$12.3K ﹤0.01% 2855
2021
Q3 		$696K Sell
49,958
-21,403
-30% -$237K ﹤0.01% 3025
2021
Q2 		$762K Buy
71,361
+23,758
+50% +$259K ﹤0.01% 3023
2021
Q1 		$628K Buy
47,603
+1,647
+4% +$27K ﹤0.01% 3014
2020
Q4 		$932K Buy
+45,956
New +$880K ﹤0.01% 2798

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Charles Schwab's FHTX Position: Q2 2026 in Review

Charles Schwab increased its Foghorn Therapeutics (FHTX) stake by 6% in Q2 2026, buying an estimated $27.8K and bringing the position to 109,781 shares worth $536K. The position accounts for ﹤0.01% of the portfolio, ranked #3221.

Charles Schwab first reported a position in FHTX in Q4 2020 and has held it in 23 quarters since. The position peaked at $1.16M in Q4 2021. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Charles Schwab held 109,781 shares of Foghorn Therapeutics worth $536K as of Q2 2026.
  • Charles Schwab bought 6,256 Foghorn Therapeutics shares in Q2 2026, an estimated $27.8K.
  • Foghorn Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3221 holding.
  • Charles Schwab first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Charles Schwab's Foghorn Therapeutics position peaked at $1.16M in Q4 2021.
  • 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.